The scientists said more evidence was needed to justify boosters.
That view disagrees with U.S. government plans to begin offering
another round of shots to many fully vaccinated Americans as soon as
next week, contingent on approval from health regulators.
As COVID-19 cases caused by the Delta variant of the virus rise,
President Joe Biden's administration is concerned that infections
among those already vaccinated are a sign that their protection is
waning and has pushed boosters as a way to rebuild immunity.
The WHO has argued that the vaccines are still needed for first
doses around the globe.
"Any decisions about the need for boosting or timing of boosting
should be based on careful analyses of adequately controlled
clinical or epidemiological data, or both, indicating a persistent
and meaningful reduction in severe disease," the scientists wrote in
the Lancet medical journal.
The risk-benefit evaluation should consider the number of severe
COVID-19 cases that boosting would be expected to prevent, and
whether it is safe and effective against the current variants, they
said.
"Current evidence does not, therefore, appear to show a need for
boosting in the general population, in which efficacy against severe
disease remains high," the scientists wrote.
Some countries have begun COVID-19 booster campaigns, including
Israel, providing some of the data on which the Biden administration
has made its case for additional shots.
[to top of second column] |
The article's authors included
the FDA Office of Vaccines Research and Review
Director Marion Gruber and Deputy Director Phil
Krause, both of whom plan to leave the agency in
the next several months. They
acknowledged that some individuals, such as those who are
immunocompromised, could benefit from an additional dose.
Broader use of boosters may be needed in the future if there is
waning immunity to the primary vaccination or if new variants evolve
so that the vaccines no longer protect against the virus, they said.
Boosters could also prove risky if introduced too soon or too
frequently, the scientists wrote.
A panel of experts that advises the FDA on vaccines plans to meet on
Sept. 17 to discuss additional doses of the Pfizer/BioNTech shot,
the first step in a wider booster roll-out.
The article's authors included WHO top scientists Soumya Swaminathan,
Ana-Maria Henao-Restrepo and Mike Ryan.
"Current vaccine supplies could save more lives if used in
previously unvaccinated populations," the authors wrote.
(Reporting by Ahmed Aboulenein; Editing by Caroline Humer and Bill
Berkrot)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
|